AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Beem stock price today per share3/28/2023 ![]() The price target for Beam Therapeutics was raised by BMO Capital Markets in a research note released on Tuesday, December 20. The previous price objective of $65.00 has been reduced to $53.00, and a “neutral” rating has been assigned to the stock. In a report made public on November 8 by Credit Suisse Group, there was a reduction in the price target projected for Beam Therapeutics. The BEAM project has, in recent times, attracted the attention and commentary of several different research organizations. Institutional investors and hedge funds collectively hold most of the company’s shares, which amounts to 76.70% of the total. ![]() Tower Research Capital LLC (TRC) now holds 34,463 shares of the company’s stock, which has a market value of $1,642,000 following the purchase of an additional 10,281 shares over the past three months. This was the last and most important item on the agenda. In the third quarter, Tower Research Capital LLC (TRC) increased the percentage of ownership it held in Beam Therapeutics by 42.5%. The current market value of these shares places the company’s value at $2,757,000.ĭuring the third quarter, Connor Clark & Lunn Investment Management Ltd invested approximately $2,034,000 in Beam Therapeutics, which was added as a new holding during that period. Following the purchase of 3,725 additional shares during the most recent quarter, Credit Suisse AG now directly owns 57,868 shares in the company. The increase in holdings that Credit Suisse AG made during the third quarter resulted in Beam Therapeutics benefiting from that increase. Pictet Asset Management SA shelled out approximately 201 000 Swiss francs during the third quarter to acquire a new investment in Beam Therapeutics.ĭuring the third quarter, Beam Therapeutics was the lucky recipient of a new investment from Envestnet Asset Management INC totaling 266,000 dollars. Purchases and sales of BEAM stock have been included in recent transactions involving major investors. The fund’s current holdings in the company amount to 8,283 shares after the sale of 4,954 shares of the company during the quarter.Īt the end of the most recent reporting period, E Fund Management Company, INC, Ltd was the owner of Beam Therapeutics stock worth a total of $395,000. ![]() Beam Global was incorporated in 2006 and is headquartered in San Diego, California.In its most recent filing with the Securities and Exchange Commission, E Fund Management Company, Ltd disclosed that it reduced its holdings in Beam Therapeutics INC (NASDAQ: BEAM) by 37.4% during the third quarter. and changed its name to Beam Global in September 2020. ![]() The company was formerly known as Envision Solar International, Inc. It is also developing EV-Standard, a lamp standard, EV charging, and emergency power product that uses an existing streetlamp's foundation and a combination of solar, wind, grid connection, and onboard energy storage to provide curbside charging and UAV ARC, an off-grid and renewably energized product and network used to charge aerial drone (UAV) fleets. The company's product portfolio include EV ARC (electric vehicle autonomous renewable charger), an infrastructure product that uses integrated solar power and battery storage to provide a source of power for factory installed electric vehicle charging stations Solar Tree DCFC, an off-grid, renewably energized, and single-column mounted smart generation and energy storage system to provide a 50kW DC fast charge to one or more electric vehicles or larger vehicles and EV ARC DCFC, a DC fast charging system for charging EVs. Beam Global, a cleantech company, designs, develops, engineers, manufactures, and sells renewably energized products for electric vehicle (EV) charging infrastructure, outdoor media and branding, and energy security products. ![]()
0 Comments
Read More
Leave a Reply. |